How HCG Affects LH

Human chorionic gonadotropin (HCG) shares structural homology with LH and binds the LH/CG receptor on testicular Leydig cells. This directly stimulates testosterone synthesis, bypassing the pituitary. The resulting testosterone elevation triggers negative feedback at the hypothalamus and pituitary, suppressing endogenous GnRH pulses and reducing natural LH secretion. On standard immunoassays, HCG may cross-react and appear as elevated LH, creating measurement artifacts. Some newer assays can distinguish HCG from LH.

At PCT-bridging doses (250-500 IU every other day), HCG stimulates testosterone production within 24-72 hours. Endogenous LH measured by standard assay may appear elevated due to HCG cross-reactivity, or may be suppressed if the assay distinguishes HCG from LH. After stopping HCG, endogenous LH should begin recovering within 1-2 weeks as the exogenous stimulus clears. At higher doses (1,000-1,500 IU three times weekly), LH suppression is more pronounced and recovery takes longer.

Do not rely on LH measurements during active HCG use, as cross-reactivity confounds results. The meaningful measurement is LH at 2-4 weeks after stopping HCG, when the exogenous stimulus has cleared and endogenous pituitary function can be assessed. Testosterone levels during HCG use reflect Leydig cell responsiveness, not HPTA recovery.

HCG is best used as a bridge to PCT (maintaining testicular function during the ester clearance window) or as a rescue therapy when SERMs alone fail to restart the axis. Prolonged HCG monotherapy (more than 4-6 weeks) can desensitize Leydig cells and further suppress endogenous LH. Transition from HCG to SERMs (clomiphene or tamoxifen) after 2-4 weeks to allow pituitary-driven recovery. If using HCG during failed PCT, overlap with SERMs for 1-2 weeks before discontinuing HCG.